MetaADEDB 2.0 @ LMMD
betamethasone sodium phosphate
(PLCQGRYPOISRTQ-LWCNAHDDSA-L)
Structure
SMILES
O=C1C=C[C@]2(C(=C1)CC[C@@H]1[C@]2(F)[C@@H](O)C[C@]2([C@H]1C[C@@H]([C@]2(O)C(=O)COP(=O)([O-])[O-])C)C)C.[Na+].[Na+]
Molecular Formula:
C22H28FNa2O8P
Molecular Weight:
516.405
Log P:
2.8891
Hydrogen Bond Acceptor:
8
Hydrogen Bond Donor:
2
TPSA:
156.83
CAS Number(s):
151-73-5
Synonym(s)
1.
betamethasone sodium phosphate
2.
Bentelan
3.
Betnesol
4.
Celestone phosphate
5.
Rinderone
6.
betamethason sodium phosphate
7.
betamethasone 21-phosphate
8.
betamethasone disodium phosphate
9.
betamethasone disodium phosphate, (11beta)-isomer
10.
betamethasone phosphate
11.
betamethasone sodium phosphate, (11beta,16beta)-isomer
External Link(s)
MeSHC028994
PubChem Compound65478
ChEBI3078
CHEMBLCHEMBL1200762
KEGGdr:D00972
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1NauseaFAERS: 5US FAERS
2ChillsFAERS: 3US FAERS
3HeadacheFAERS: 3US FAERS
4PalpitationsFAERS: 3US FAERS
5SyncopeFAERS: 3US FAERS
6Anaphylactic shockFAERS: 2US FAERS
7AngioedemaFAERS: 2US FAERS
8CellulitisFAERS: 2US FAERS
9Corneal UlcerFAERS: 2US FAERS
10DizzinessFAERS: 2US FAERS
11ErythemaFAERS: 2US FAERS
12Injection site necrosisFAERS: 2US FAERS
13Maternal exposure during pregnancyFAERS: 2US FAERS
14ShockFAERS: 2US FAERS
15UrticariaFAERS: 2US FAERS
16VertigoFAERS: 2US FAERS
17Wrong technique in drug usage processFAERS: 2US FAERS
18Abdominal PainFAERS: 1US FAERS
19Anaphylactoid ReactionFAERS: 1US FAERS
20Bladder painFAERS: 1US FAERS
21Blood urea increasedFAERS: 1US FAERS
22BronchospasmFAERS: 1US FAERS
23Chest PainFAERS: 1US FAERS
24Conjunctival erosionFAERS: 1US FAERS
25Corneal OpacityFAERS: 1US FAERS
26Corneal PerforationFAERS: 1US FAERS
27Corneal epithelium disorderFAERS: 1US FAERS
28Culture positiveFAERS: 1US FAERS
29Diabetes mellitus inadequate controlFAERS: 1US FAERS
30DisorientationFAERS: 1US FAERS
31DyspepsiaFAERS: 1US FAERS
32DysuriaFAERS: 1US FAERS
33Eye painFAERS: 1US FAERS
34Feeling abnormalFAERS: 1US FAERS
35FlushingFAERS: 1US FAERS
36General physical health deteriorationFAERS: 1US FAERS
37GlaucomaFAERS: 1US FAERS
38HypersensitivityFAERS: 1US FAERS
39HypotensionFAERS: 1US FAERS
40HysterectomyFAERS: 1US FAERS
41Inappropriate schedule of drug administrationFAERS: 1US FAERS
42Incorrect route of drug administrationFAERS: 1US FAERS
43IndurationFAERS: 1US FAERS
44InfarctionFAERS: 1US FAERS
45Injection site painFAERS: 1US FAERS
46Intraspinal abscessFAERS: 1US FAERS
47IridoceleFAERS: 1US FAERS
48KeratopathyFAERS: 1US FAERS
49Limb injuryFAERS: 1US FAERS
50Listeria test positiveFAERS: 1US FAERS
51Lower motor neurone lesionFAERS: 1US FAERS
52MenorrhagiaFAERS: 1US FAERS
53Mental impairmentFAERS: 1US FAERS
54Myocardial InfarctionFAERS: 1US FAERS
55PallorFAERS: 1US FAERS
56PemphigusFAERS: 1US FAERS
57PneumoniaFAERS: 1US FAERS
58Procedural complicationFAERS: 1US FAERS
59Protein urine presentFAERS: 1US FAERS
60PruritusFAERS: 1US FAERS
61PurulenceFAERS: 1US FAERS
62Respiratory FailureFAERS: 1US FAERS
63Respiratory arrestFAERS: 1US FAERS
64Respiratory distressFAERS: 1US FAERS
65SepsisFAERS: 1US FAERS
66Skin test positiveFAERS: 1US FAERS
67Stevens-Johnson SyndromeFAERS: 1US FAERS
68SynovitisFAERS: 1US FAERS
69Toxicity to various agentsFAERS: 1US FAERS
70Umbilical cord vascular disorderFAERS: 1US FAERS
71Unevaluable eventFAERS: 1US FAERS
72Hearing Loss15318963CTD
73Optic Neuritis655214CTD
74Tinnitus15318963CTD
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120269

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.